Brian Orelli - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Brian Orelli's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Brian Orelli
Verified
Freelance Writer and Analyst, The Motley Fool (U.S.)
San Diego
Beats
Business Trivia Tech & LifestyleFinance History
Military, economics,
Content
By Brian Orelli| BioWorld Verified Home » Glycomine snags $115M to advance its PMM2-CDG treatmentGlycomine snags $115M to advance its PMM2-CDG treatmentGlycomine Inc. secured $115 million in a series C financing round to support the advancement of GLM-101 into a phase IIb study in patients with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG). BioWorld Financings Endocrine/metabolic Small molecule Series C U.S.
By Brian Orelli| BioWorld Verified Home » Hillstar launches with $67M series A to target TRBV9+ T cells BioWorld briefs for March 25, 2025. BioWorld MedTech briefs for March 25, 2025 U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example... Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...
By Brian Orelli| BioWorld Verified Home » Glycomine snags $115M to advance its PMM2-CDG treatmentGlycomine snags $115M to advance its PMM2-CDG treatmentGlycomine Inc. secured $115 million in a series C financing round to support the advancement of GLM-101 into a phase IIb study in patients with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG). BioWorld Financings Endocrine/metabolic Small molecule Series C U.S.
Company Info
The Motley Fool (U.S.)
San Diego, United States